NO120033B - - Google Patents
Download PDFInfo
- Publication number
- NO120033B NO120033B NO167168A NO167168A NO120033B NO 120033 B NO120033 B NO 120033B NO 167168 A NO167168 A NO 167168A NO 167168 A NO167168 A NO 167168A NO 120033 B NO120033 B NO 120033B
- Authority
- NO
- Norway
- Prior art keywords
- parts
- pyrazine
- formula
- derivatives
- solution
- Prior art date
Links
- 238000000034 method Methods 0.000 claims description 8
- 150000003216 pyrazines Chemical class 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 claims description 3
- 239000013067 intermediate product Substances 0.000 claims description 3
- IVRLZJDPKUSDCF-UHFFFAOYSA-N pyrazin-2-ylhydrazine Chemical class NNC1=CN=CC=N1 IVRLZJDPKUSDCF-UHFFFAOYSA-N 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
- 150000002366 halogen compounds Chemical class 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 2
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical compound OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical class OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 description 1
- GELVZYOEQVJIRR-UHFFFAOYSA-N 2-chloropyrazine Chemical class ClC1=CN=CC=N1 GELVZYOEQVJIRR-UHFFFAOYSA-N 0.000 description 1
- -1 2-ethoxy-carbonyl-5-methyl-3-n-propylpyrazine Chemical compound 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Analogifremgangsmåte for fremstilling av nye, Analogy method for the production of new,
terapeutisk virksomme pyrazinderivater. therapeutically active pyrazine derivatives.
Oppfinnelsen vedrører en fremgangsmåte for fremstilling av nye pyrazinderivater som forhindrer bronkospasme og som derfor er nyttige i behandlingen av sykdommer som omfatter spasme eller sammentrekning av bronkial-muskulaturen, for eksempel astma eller bronkitt. The invention relates to a method for the production of new pyrazine derivatives which prevent bronchospasm and which are therefore useful in the treatment of diseases which include spasm or contraction of the bronchial muscles, for example asthma or bronchitis.
I henhold til oppfinnelsen tilveiebringes en fremgangsmåte for fremstilling av pyrazinderivater med formelen: According to the invention, a method is provided for the production of pyrazine derivatives with the formula:
hvor R og R , som kan være like eller forskjellige.^står, for alkyl-radikaler med 1-4 karbonatomer, og X står for étj hydroksyl-radikal, som omfatter at et pyrazinylhydrazin-derivat'med formelen: hvor R og R har den ovenfor angitte betydning, omsettes med en reaktiv ester eller halogen-forbindelse avledet fra karbonsyre, og, om nødvendig, behandles et eventuelt oppnådd mellomprodukt med en base....... — - - - En egnet reaktiv ester eller-Jialpgen-forbindelse, -avledet fra karbonsyre er for eksempel, en -lavere 'alkyléster' av klor-maursyre, for reksempel etyl-klorformiat,...eller karbonylklorid. -f - -••'Det :'skal "forståes slik'åt1 når 'en slaver é alkylester av klor-maursyre brukes i ovennevnte fremgangsmåte, .er det.nødvendig å behandle det mellomprodukt som oppnås med en base, for eksempel natrium-hydroksyd, for å oppnå 'et pyrazin-derivat ifølge opp--finnelsen hvor X står for et hydroksyl-radikal. where R and R, which may be the same or different, stand for alkyl radicals with 1-4 carbon atoms, and X stands for one hydroxyl radical, which includes a pyrazinylhydrazine derivative with the formula: where R and R have the meaning given above, is reacted with a reactive ester or halogen compound derived from carbonic acid, and, if necessary, any intermediate product obtained is treated with a base....... — - - - A suitable reactive ester or-Jialpgen- compound, -derived from carboxylic acid is, for example, a -lower 'alkyl ester' of chloroformic acid, for example ethyl chloroformate,...or carbonyl chloride. -f - -••'It :'shall be "understood that" when a slaver and alkyl ester of chloroformic acid is used in the above process, it is necessary to treat the intermediate product obtained with a base, for example sodium hydroxide, to obtain a pyrazine derivative according to the invention where X stands for a hydroxyl radical.
Pyrazin-derivatene som kan fremstilles ved fremgangsmåten ifølge oppfinnelsen, har en skjelett-ringstruktur med formelen: The pyrazine derivatives that can be prepared by the method according to the invention have a skeletal ring structure with the formula:
som-er''s-triazoi/4, 3-a/pyrazin; og denne struktur er nummerert som vist ovenfor! as-er''s-triazoli/4,3-a/pyrazine; and this structure is numbered as shown above!
2 En passende verdi for R eller R _ er for eksempel metyl- élier n-jiropyl-radikalet, og en foretrukken gruppe pyrazin-derivater omfatter de forbindelser hvoir R og R står for alkyl-radikaler som tilsammen ikke inneholder, mer enn 5 karbonatomer. 2 A suitable value for R or R _ is, for example, the methyl-elier n-jiropyl radical, and a preferred group of pyrazine derivatives includes those compounds where R and R stand for alkyl radicals which together do not contain more than 5 carbon atoms.
Et spesifikt pyrazin-derivat som kan fremstilles ved fremgangsmåten ifølge oppfinnelsen er for eksempel 3-hydroksy-6-metyl-8-n-propyl-s-triazol/4,3-a/pyrazin. A specific pyrazine derivative which can be prepared by the method according to the invention is, for example, 3-hydroxy-6-methyl-8-n-propyl-s-triazole/4,3-a/pyrazine.
Pyrazinylhydrazin-derivaténe. som brukes som utgangs-materialer i ovennevnte fremgangsmåter, kan oppnåes ved omsetning av de tilsvarende halogenpyrazin-derivater,, for eksempel de tilsvarende klorpyrazin-derivater, med hydrazin, og halogenpyrazin-derivatene selv kan oppnåes ved omsetning av de tilsvarende hydroksypyrazin-der.ivater med., et. f.osforoksyhalpgenid, . for eksempel fosforoksyklorid... „0r.„ The pyrazinylhydrazine derivs. which are used as starting materials in the above methods, can be obtained by reacting the corresponding halopyrazine derivatives, for example the corresponding chloropyrazine derivatives, with hydrazine, and the halopyrazine derivatives themselves can be obtained by reacting the corresponding hydroxypyrazine derivatives with., et. f.osphoroxyhalpgenide, . for example phosphorus oxychloride... „0r.„
Oppfinnelsen skal belyses ved følgende eksempler. The invention shall be illustrated by the following examples.
Deler betyr vektdeler. Parts means parts by weight.
Eksempel 1 Example 1
En oppløsning av 3,2 deler .vannfritt natriumacetat i A solution of 3.2 parts .anhydrous sodium acetate i
9 deler vann tilsettes til en oppløsning av 2 deler 2-hydrazin-5-metyl-3-n-propylpyrazin og 2 deler"iséddik i 25 deler etanol. Blandingen oppvarmes til alt fast stoff er oppløst og avkjøles der-o"' etter til 0°C. En strøm av fosgen ledes gjennom oppløsningen i. 10. minutter, og pH-verdien holdes på 5 ved tilsetning av vannfritt ' natriumacetat. Blandingen inndampes deretter ved 50°C,. og residuet suspenderes i 60 deler 0,5n natriumhydroksyd-oppløsning. Den resulterende suspensjon oppvarmes i 5 minutter ved 50 oC, avkjøles 9 parts of water are added to a solution of 2 parts of 2-hydrazine-5-methyl-3-n-propylpyrazine and 2 parts of glacial acetic acid in 25 parts of ethanol. The mixture is heated until all solids are dissolved and then cooled until 0°C. A stream of phosgene is passed through the solution for 10 minutes, and the pH is maintained at 5 by the addition of anhydrous sodium acetate. The mixture is then evaporated at 50°C. and the residue is suspended in 60 parts of 0.5N sodium hydroxide solution. The resulting suspension is heated for 5 minutes at 50 oC, cooled
o o
deretter til 0 C og den overstående.væske dekanteres fra et olje-aktig residuum. Denne væske behandles med karbon, filtreres og filtratet surgjøres med iseddik.''bet utfelte faste stoff filtreres vekk, vaskes, tørkes og rekrystalliseres fra metanol. Således oppnåes 3-hydroksy-6-metyl-8-n-propyl-s-triåzol/4,3-a/pyrazin-som "blék-gule krystaller med smeltepunkt l83-184°c."" then to 0 C and the supernatant liquid is decanted from an oily residue. This liquid is treated with carbon, filtered and the filtrate acidified with glacial acetic acid. The precipitated solid is filtered off, washed, dried and recrystallized from methanol. Thus, 3-hydroxy-6-methyl-8-n-propyl-s-triazole/4,3-a/pyrazine-like "pale yellow crystals with melting point 183-184°C" are obtained.
Eksempel 2 Example 2
En oppløsning av 3,5 deler etyl-klorformiat i 15 A solution of 3.5 parts of ethyl chloroformate in 15
deler etylacetat tilsettes langsomt under omrøring til en oppløs-ning av 5,1 deler 2-hydrazin-5-metyl-3-n-propylpyrazin ,i .50, deler etylacetat. Reaksjonstemperaturen holdes ved 20-25°C. Etter 1 time filtreres den resulterende suspensjon. Det faste stoff opp-løses i 35 deler vann og nøytraliseres ved tilsetning av natriumacetat. Det gule utfellingsprodukt som danner seg, samles og rekrystalliseres fra cykloheksan for å gi 2-etoksy-karbonyl-5-metyl-3-n-propylpyrazin med smeltepunkt 97-98°C. 2 deler av denne forbindelse kokes i 5 minutter i 20 deler vann og 3 deler av en 40 % oppløsning av natriumhydroksyd i vann. Oppløsningen som danner seg, omrøres med trekull og filtreres. Filtratet justeres til pH 5 ved tilsetning av eddiksyre. Utfellingsproduktet som danner seg, samles og rekrystalliseres fra metanol, og det oppnåes 3-hydroksy-6-metyl-8-n-propyl-s-triazol/4,3-a/pyrazin som blekgule nåler med smeltepunkt 183-184°c. parts of ethyl acetate are added slowly with stirring to a solution of 5.1 parts of 2-hydrazine-5-methyl-3-n-propylpyrazine in .50 parts of ethyl acetate. The reaction temperature is kept at 20-25°C. After 1 hour, the resulting suspension is filtered. The solid is dissolved in 35 parts water and neutralized by adding sodium acetate. The yellow precipitate that forms is collected and recrystallized from cyclohexane to give 2-ethoxy-carbonyl-5-methyl-3-n-propylpyrazine, mp 97-98°C. 2 parts of this compound are boiled for 5 minutes in 20 parts of water and 3 parts of a 40% solution of sodium hydroxide in water. The resulting solution is stirred with charcoal and filtered. The filtrate is adjusted to pH 5 by adding acetic acid. The precipitate that forms is collected and recrystallized from methanol, and 3-hydroxy-6-methyl-8-n-propyl-s-triazole/4,3-a/pyrazine is obtained as pale yellow needles with a melting point of 183-184°c.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO167168A NO120033B (en) | 1967-02-03 | 1968-04-30 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB5356/67A GB1146770A (en) | 1967-02-03 | 1967-02-03 | S-triazolo[4,3-a]pyrazine derivatives |
NO0419/68A NO119839B (en) | 1967-02-03 | 1968-02-02 | |
NO167168A NO120033B (en) | 1967-02-03 | 1968-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO120033B true NO120033B (en) | 1970-08-17 |
Family
ID=27254618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO167168A NO120033B (en) | 1967-02-03 | 1968-04-30 |
Country Status (1)
Country | Link |
---|---|
NO (1) | NO120033B (en) |
-
1968
- 1968-04-30 NO NO167168A patent/NO120033B/no unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU520041A3 (en) | The method of producing amides of aromatic carboxylic acids or their salts | |
US2554816A (en) | Heterocyclic sulfonamides and methods of preparation thereof | |
WO2017186140A1 (en) | Method for preparing tyrosine kinase inhibitor and derivative thereof | |
JPS60120872A (en) | Novel heterocyclic compound and cardiotonic agent | |
US2965643A (en) | Derivatives of pyrazolo | |
JPS61155358A (en) | Diallylbutyric acid derivative and production thereof | |
US2484029A (en) | Hydrazine derivatives of pyridazine compounds | |
US3316266A (en) | 3-aminopyrazinoic acid derivatives and process for their preparation | |
NO120033B (en) | ||
US3213094A (en) | Method of preparing quinazolones | |
Lutz et al. | Antimalarials. The Synthesis of 2, 4, 7-Trichloroquinoline1 | |
US2572728A (en) | Hydroxybenzenesulfonamidopyra-zines and preparation of same | |
US3025299A (en) | New carbostyril derivatives | |
DE1695702C3 (en) | Process for the preparation of 1-acyl-2-carboxy-3-indolylacetic acids | |
US2650232A (en) | 2-methyl-3-amino-4,5-di-hydroxymethylpyridine and its salts and the preparation thereof | |
US3849436A (en) | Cyclization of 2-(3-aryl-5-pyrazolyl)benzoic acids,esters and amides to 2-arylpyrazolo(5,1-a)isoindol-8-ones | |
US2524802A (en) | Hydroxybenzenesulfonamidopyridazines and preparation of same | |
PL80904B1 (en) | ||
NO138978B (en) | PROCEDURE AND APPARATUS FOR STRUCTURAL TREATMENT OF MEAT, MIXTURES OF MEAT AND / OR MEAT WASTE OR INDEAL AND / OR NON-MEAT SUBSTANCES | |
US2389147A (en) | 4' methoxy 5 halogeno diphenylamino 2' carboxyl compound and process for producing the same | |
US2532055A (en) | Pyridone derivatives | |
NO162156B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE TRICYCLIC TIADIAZINO DERIVATIVES | |
NO162019B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE PYRIMIDOISKINOLIN DERIVATIVES. | |
US3065225A (en) | N', n4-di-isoxazolylcarbonyl-sulfanilamide derivatives | |
US2674614A (en) | Thiocarbhydrazine compounds |